Trulieve Cannabis (OTCMKTS:TCNNF) Price Target Cut to $6.50

Trulieve Cannabis (OTCMKTS:TCNNF) had its target price decreased by investment analysts at Needham & Company LLC from $9.00 to $6.50 in a research report issued on Thursday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Needham & Company LLC’s target price would suggest a potential upside of 20.37% from the company’s previous close.

Other research analysts have also recently issued reports about the stock. Wedbush dropped their target price on shares of Trulieve Cannabis from $8.00 to $6.00 and set an “outperform” rating on the stock in a research note on Friday, August 11th. Stifel Nicolaus boosted their target price on shares of Trulieve Cannabis from C$8.00 to C$9.00 in a research note on Thursday, August 10th.

Trulieve Cannabis Stock Performance

Trulieve Cannabis stock opened at $5.40 on Thursday. Trulieve Cannabis has a fifty-two week low of $3.42 and a fifty-two week high of $16.11. The firm’s 50-day simple moving average is $5.54 and its 200 day simple moving average is $4.75.

Trulieve Cannabis Company Profile

Trulieve Cannabis Corp., together with its subsidiaries, operates as a medical cannabis company. The company cultivates and produces products in-house and distributes its products to Trulieve branded stores (dispensaries) in Florida, as well as through home delivery. It produces flowers, edibles, vaporizer cartridge, concentrates, topicals, capsules, tinctures, dissolvable powders, and nasal sprays under the Avenue, Cultivar Collection, Muse, Modern Flower, Alchemy, Momenta, Sweet Talk, Co2lors, Loveli, and Roll One brands.